News & Events
Histone Modifying Proteins, Not Histones, Remain Associated with DNA through Replication, Say Epigenetic Researchers
Thomas Jefferson University team shifts a longstanding paradigm for epigenetic marks.
Thomas Jefferson University Renames its Graduate School
The Jefferson College of Graduate Studies has been renamed the Jefferson Graduate School of Biomedical Sciences (JGSBS) to better reflect the school's breadth of degrees and...
Breast Cancer Patients Who Lack RB Gene Respond Better to Neoadjuvant Chemotherapy
Breast cancer patients whose tumors lacked the retinoblastoma tumor suppressor gene (RB) had an improved pathological response to neoadjuvant chemotherapy, researchers at Thomas Jefferson University...
Jefferson School of Pharmacy's Doctor of Pharmacy Program Receives Accreditation
The Doctor of Pharmacy program offered by Jefferson School of Pharmacy of Thomas Jefferson University has been accredited by the Accreditation Council for Pharmacy Education.
ATP: From Bystander to Actor in Kinase Regulation
A new function of ATP—beyond its passive roles as an energy source and a phosphate donor for phosphorylation reactions—was unraveled by Jefferson researchers.
HIV Drug May Slow Down Metastatic Breast Cancer, Researchers at Jefferson's Kimmel Cancer Center Report
Study finds that HIV receptor CCR5 is induced by oncogenes in breast cancer cells, too.
Japan Center Established
In January 2012 the Japan Center for Health Professions Education and Research at Jefferson was established between Thomas Jefferson University, and the Japanese Association for the Development of...
Jefferson's Kimmel Cancer Center to Host Tribute Dinner Honoring Steve Sabol, President of NFL Films
For demonstrating great strength and dignity through a battle with brain cancer, Mr. Sabol will be honored with the Spirit of Courage Award.
A Closer Look at PARP-1 Reveals Potential New Drug Targets
Researchers at Jefferson's Kimmel Cancer Center capture a major chemotherapeutic target in complex with DNA damage, revealing novel targets for new PARP-1 inhibitors.
Jefferson Receives $2.6 Million NIH Grant to Study Imaging Method to Stage Prostate Cancer Without Biopsy
Thomas Jefferson University researchers will investigate imaging agent Cu-64, a biomolecule that selectively seeks out a prostate tumor biomarker.